Omzo vs Willow: Clinician-Guided Compounded Care vs Structured Follow-Up

Quick verdict: Omzo focuses on clinician-guided access to compounded semaglutide and tirzepatide with medication costs disclosed as starting at $179 for semaglutide and $279 for tirzepatide, while Willow emphasizes an oral GLP-1 program priced from $299 that pairs telehealth with progress tracking and structured follow-up. Choose based on whether you prioritize compounded medication access and lower starting price or a structured digital follow-up model.

Explore Omzo clinician-guided plans

Omzo vs Willow: service model and clinical oversight

Both providers use licensed clinicians but they frame clinical care differently. Omzo connects users with licensed U.S. providers who review plans and may prescribe medication based on professional judgment. Omzo notes that providers make final determinations about prescribing and that the platform is not a medical practice. Willow is telehealth-first and states treatment is available only when a licensed clinician determines it is medically appropriate, with follow-up consultations included as part of a structured weight management journey.

See Willow telehealth program and follow-up

Five key differences that matter for most users

1. Medication format and sourcing

Omzo highlights compounded semaglutide and tirzepatide supplied through a compounded medication program produced by state-licensed sterile compounding pharmacies and notes these compounded drugs are not FDA-approved. Omzo also says clinicians may write prescriptions for branded medications but Omzo does not sell, dispense, or ship branded drugs. Willow promotes an oral GLP-1 program; its materials emphasize a structured program rather than a medication subscription. Willow also cautions that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.

2. Pricing and starting costs

The sources list Omzo starting prices as $179 for semaglutide and $279 for tirzepatide. Willow lists a starting price of 299. Any additional membership, shipping, renewal, or pharmacy costs are not detailed in the captured Willow content. Omzo states medication costs are included in fees collected by Omzo and Omzo pays the pharmacies, but Omzo also warns pricing, eligibility, pharmacy, state coverage and renewal terms may change.

3. Program focus and support

Willow positions its offering as a structured weight management journey with progress tracking tools and follow-up consultations intended to convert GLP-1 efficacy into sustainable results. Omzo emphasizes clinician-guided GLP-1 care with fast, discreet delivery and notes FSA and HSA eligibility, focusing primarily on access to compounded and prescription options through clinician review.

4. Regulatory and safety language

Omzo repeatedly states that compounded medications are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality. Willow captured text advises confirming medication-specific approval status and notes that branded and compounded products are not interchangeable. Both sources make clinician review and appropriateness central to access.

5. Eligibility and prescribing discretion

Both sources indicate that licensed clinicians determine eligibility. Omzo stresses that providers make the final determination and that the Omzo assessment does not create a doctor patient relationship. Willow says treatment is available only when a licensed clinician determines it is medically appropriate.

Comparison table: Omzo vs Willow

Practical considerations from the captured facts

If your priority is access to compounded weekly injectables at a lower listed starting price and you accept that compounded drugs are not FDA-approved, Omzo presents a clinician-guided path with medication costs shown for semaglutide and tirzepatide and with medication fees included in Omzo’s collected fees. If you want an oral GLP-1 regimen wrapped in progress tracking and structured follow-up, and you value a program oriented around behavior change, Willow positions itself around that model with an entry price listed as 299.

Compare Omzo medication options

Review Willow follow-up features

Start Omzo eligibility check

Conclusion: Choose based on what matters most

Choose Omzo if you want clinician-guided access to compounded semaglutide or tirzepatide with listed starting prices of $179 and $279 respectively, and if you accept that compounded medications are not FDA-approved and that providers make final prescribing decisions. Choose Willow if you prefer an oral GLP-1 program built around telehealth, progress tracking, and structured follow-up, with a listed starting price of 299 and treatment available only when a licensed clinician determines it is medically appropriate.